GUSHENGTANG (02273) reaches strategic cooperation with 1doc to create a new integrated Chinese-Western medical service model in Singapore.

On October 22, GUSHENGTANG (02273) reached a strategic cooperation agreement with the comprehensive digital healthcare platform 1doc in Singapore. Both parties will systematically introduce traditional Chinese medicine services into Western medical family clinics in Singapore, providing the public with a comprehensive experience of integrated traditional Chinese and Western medicine in clinical treatment, daily healthcare, and community health. This cooperation is an important milestone for GUSHENGTANG in deeply integrating traditional Chinese medicine into the mainstream medical system in Singapore, and it is of great significance for promoting the internationalization of traditional Chinese medicine. At the signing ceremony, Dr. Lam Pin Min, former Senior Minister of State for Health and Transport of Singapore and Chairman of IHG, Ms. Juliana Xie, Founder and CEO of IHG, Mr. Tu Zhiliang, Founder and Chairman of GUSHENGTANG, and Ms. Lin Xiaoyan and Ms. Zheng Xiang, Vice Presidents of GUSHENGTANG, attended as representatives of both parties. According to the cooperation framework, 1doc will set up independent traditional Chinese medicine treatment areas within its existing clinic network. GUSHENGTANG will hold a 70% stake and take full responsibility for operation and management, while 1doc will hold a 30% stake and jointly carry out traditional Chinese medicine business. This ownership structure ensures the deep integration and professional operation of traditional Chinese medicine services in a Western medical setting. Through this cooperation model, patients can receive integrated traditional Chinese and Western medicine treatment plans within the same healthcare ecosystem, experiencing full-cycle health management from prevention, diagnosis, to rehabilitation. During the treatment process, traditional Chinese medicine physicians from GUSHENGTANG may prescribe necessary tests and examinations for patients to enhance the objectivity and accuracy of diagnosis, and use clear quantitative indicators to enhance patients' understanding and trust in the treatment plan, thus improving patient compliance. The Singapore government has been actively promoting the integration of traditional Chinese and Western medicine. In 2025, the Singapore Ministry of Health launched the "Traditional Chinese Medicine Integration Sandbox Program", which tests and evaluates traditional Chinese medicine treatment plans in public healthcare institutions based on evidence-based medicine and cost-effectiveness. This policy initiative fully embodies the direction of "complementary advantages of traditional Chinese and Western medicine", providing strong policy support for the cooperation between GUSHENGTANG and 1doc. 1doc is a subsidiary of the leading healthcare company IHG (IAPPS Health Group) in Singapore, operating 9 self-owned clinics and 21 affiliated clinics in Singapore. With technology platforms such as 1doc CIS (Clinic Information System) and digital twinning, it promotes the landing of personalized, predictive, and preventive "3P medicine" model. Currently, 1doc has served over 79,000 patients, supported more than 300 corporate clients, and provided workplace health services for over 25,000 employees, providing strong local medical network and digital technology support for the landing of traditional Chinese medicine in Singapore. As the first listed traditional Chinese medicine service organization in China, GUSHENGTANG has opened over 80 offline medical institutions in China and Singapore, serving over 20 million customers. In its 15 years of establishment, GUSHENGTANG has accumulated a large amount of high-quality clinical data, with over 18 million medical records and over 40 million clinical prescriptions, laying a solid evidence-based foundation for verifying the clinical efficacy of traditional Chinese medicine, ensuring patient safety, and evaluating cost-effectiveness. This cooperation, based on holding operation, aims to create a "new Chinese medicine" service model in Singapore, is an important exploration of GUSHENGTANG's digital integration into the international mainstream medical system. In the future, both parties will explore more single-store partnership models, build a synergistic new ecosystem of collaborative diagnosis and treatment "co-creation, co-governance, and sharing", accelerate the standardized and scaled development of traditional Chinese medicine in the international market. Singapore's policy innovation and market openness in the field of integration of traditional Chinese and Western medicine provide a high standard international experimental field for GUSHENGTANG. The technological solutions, compliance experience, and operation mode formed by this cooperation are expected to be replicated in Southeast Asia and even global markets in the future, helping traditional Chinese medicine gain broader international recognition within the framework of evidence-based medicine.